rb1 c Search Results


86
Thermo Fisher snp rb1 c 3121415 10
Snp Rb1 C 3121415 10, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rb1+c/SNP+RB1%2C+C___3121415_10/pm20508609-38-14-15
Average 86 stars, based on 1 article reviews
snp rb1 c 3121415 10 - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

90
MyBiosource Biotechnology rb1 c-terminal peptide
a , Structures of two inhibitors of the CCNE1:CDK2 complex – I-125A and I-198 – reported in a patent . b, ADP-Glo data showing effects of the indicated compounds on the activity of a purified N112C-CCNE1:CDK2 complex as measured by phosphorylation of the C-terminal peptide of <t>RB1</t> (left) or the histone H1 protein (right). The N112C-CCNE1:CDK2 complex was pre-treated with compounds for 2 h (37 °C) before initiating phosphorylation reactions by addition of substrate. CI, confident intervals. Data represent average values ± s.e.m., n = 3. c , Gel-ABPP data showing concentration-dependent partial blockade of YZ-01-A engagement of N112-CCNE1 by I-125A and I-198, but not dinaciclib. Assays were performed in lysates from transfected HEK293T cells co-expressing NLuc-N112C-CCNE1 or NLuc-WT-CCNE1 and CDK2 that were treated with the indicated concentration ranges of compounds followed by YZ-01-A (10 μM, 90 min), anti-FLAG immunoprecipitation, and processing for gel-ABPP. d , Quantification of gel-ABPP data shown in c . Data represent average values ± s.e.m., n = 3. e , NanoBRET-ABPP data showing concentration-dependent partial blockade of YZ-01-A engagement of N112-CCNE1 by I-125A and I-198. Samples were treated with compounds as described in c prior to NanoBRET measurement. Data represent average values ± s.e.m., n = 3. f , Quantification of gel- and NanoBRET-ABPP data showing that dinaciclib does not substantially affect YZ-01-A engagement of N112C-CCNE1. Data represent average values ± s.e.m., n = 3.
Rb1 C Terminal Peptide, supplied by MyBiosource Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rb1+c/rb1+c+terminal+peptide/pmc10827202-166-93-96
Average 90 stars, based on 1 article reviews
rb1 c-terminal peptide - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

86
Dawley Inc ginsenoside rb1 restored cardiac function in isoproterenol iso induced heart failure model
Modulation of signaling pathways by ginsenosides in exerting cardioprotective effect. Abbreviation ; Parkin signaling pathway (PINK), interleuking-1-beta (IL-1β), interleukin-6 (IL6), tumor necrosis factor (TNF), extracellular signal-regulated kinase (ERK1/2), c-Jun N-terminal kinase (JNK), nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1), sirutnin1 (SIRT1), nuclear factor kappa B (NF-κB), phosphoinositide3-kinase (PI3K), protein kinase B (Akt), mitogen-activated protein kinases (MAPK), yes-associated protein (YAP), ginsenoside Rg1 (Rg1), ginsenoside Rg3 (Rg3), ginsenoside <t>Rb1</t> (Rb1), ginsenoside F 2 (F 2 ).
Ginsenoside Rb1 Restored Cardiac Function In Isoproterenol Iso Induced Heart Failure Model, supplied by Dawley Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rb1+c/c+rb1/pmc12805542-96-1-14
Average 86 stars, based on 1 article reviews
ginsenoside rb1 restored cardiac function in isoproterenol iso induced heart failure model - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

N/A
Store at -20°C for up to 24 months upon receiving the product.http://www.creative-diagnostics.com/RB1-antibody-241014-147.htm
  Buy from Supplier

N/A
Rabbit Anti-Human RB1 (C-term) Antibody, 400 µl
  Buy from Supplier

N/A
Rb RB1 C term rabbit polyclonal antibody
  Buy from Supplier

Image Search Results


a , Structures of two inhibitors of the CCNE1:CDK2 complex – I-125A and I-198 – reported in a patent . b, ADP-Glo data showing effects of the indicated compounds on the activity of a purified N112C-CCNE1:CDK2 complex as measured by phosphorylation of the C-terminal peptide of RB1 (left) or the histone H1 protein (right). The N112C-CCNE1:CDK2 complex was pre-treated with compounds for 2 h (37 °C) before initiating phosphorylation reactions by addition of substrate. CI, confident intervals. Data represent average values ± s.e.m., n = 3. c , Gel-ABPP data showing concentration-dependent partial blockade of YZ-01-A engagement of N112-CCNE1 by I-125A and I-198, but not dinaciclib. Assays were performed in lysates from transfected HEK293T cells co-expressing NLuc-N112C-CCNE1 or NLuc-WT-CCNE1 and CDK2 that were treated with the indicated concentration ranges of compounds followed by YZ-01-A (10 μM, 90 min), anti-FLAG immunoprecipitation, and processing for gel-ABPP. d , Quantification of gel-ABPP data shown in c . Data represent average values ± s.e.m., n = 3. e , NanoBRET-ABPP data showing concentration-dependent partial blockade of YZ-01-A engagement of N112-CCNE1 by I-125A and I-198. Samples were treated with compounds as described in c prior to NanoBRET measurement. Data represent average values ± s.e.m., n = 3. f , Quantification of gel- and NanoBRET-ABPP data showing that dinaciclib does not substantially affect YZ-01-A engagement of N112C-CCNE1. Data represent average values ± s.e.m., n = 3.

Journal: bioRxiv

Article Title: Expanding the ligandable proteome by paralog hopping with covalent probes

doi: 10.1101/2024.01.18.576274

Figure Lengend Snippet: a , Structures of two inhibitors of the CCNE1:CDK2 complex – I-125A and I-198 – reported in a patent . b, ADP-Glo data showing effects of the indicated compounds on the activity of a purified N112C-CCNE1:CDK2 complex as measured by phosphorylation of the C-terminal peptide of RB1 (left) or the histone H1 protein (right). The N112C-CCNE1:CDK2 complex was pre-treated with compounds for 2 h (37 °C) before initiating phosphorylation reactions by addition of substrate. CI, confident intervals. Data represent average values ± s.e.m., n = 3. c , Gel-ABPP data showing concentration-dependent partial blockade of YZ-01-A engagement of N112-CCNE1 by I-125A and I-198, but not dinaciclib. Assays were performed in lysates from transfected HEK293T cells co-expressing NLuc-N112C-CCNE1 or NLuc-WT-CCNE1 and CDK2 that were treated with the indicated concentration ranges of compounds followed by YZ-01-A (10 μM, 90 min), anti-FLAG immunoprecipitation, and processing for gel-ABPP. d , Quantification of gel-ABPP data shown in c . Data represent average values ± s.e.m., n = 3. e , NanoBRET-ABPP data showing concentration-dependent partial blockade of YZ-01-A engagement of N112-CCNE1 by I-125A and I-198. Samples were treated with compounds as described in c prior to NanoBRET measurement. Data represent average values ± s.e.m., n = 3. f , Quantification of gel- and NanoBRET-ABPP data showing that dinaciclib does not substantially affect YZ-01-A engagement of N112C-CCNE1. Data represent average values ± s.e.m., n = 3.

Article Snippet: Briefly, different CCNE: CDK2 purified complexes at 4 ng μL −1 were mixed 1:1 with 2x compound stock (Both are made in kinase reaction buffer (40 mM Tris [pH = 7.6], 20 mM MgCl 2 , 0.1 mg mL −1 BSA and 50 μM DTT) and incubated at 37 °C for 1 h. Then 6 ng compound treated CCNE: CDK2 complexes (3 μL) were mixed with 2μL ATP/ CDK2 substrate mix to make final concentration of 150 μM ATP and 0.5 μg substrate per reaction (Substrate used is either histone H1(Sigma-Aldrich, 14-155) or RB1 C-terminal peptide (MyBioSource, MBS143254)), then incubated at room temperature for 1 h. Subsequently, 5 μL ADP-Glo reagent was added and incubated for 40 min at room temperature, followed with 10 μL kinase glo reagent and another 30-min incubation.

Techniques: Activity Assay, Purification, Concentration Assay, Transfection, Expressing, Immunoprecipitation

a, b , ADP-Glo data showing effects of the indicated compounds on the activity of a purified WT-CCNE1:CDK2 ( a ) or WT-CCNE2:CDK2 ( b ) complexes as measured by phosphorylation of the C-terminal peptide of RB1 (left) or the histone H1 protein (right). The WT-CCNE:CDK2 complexes were pre-treated with compounds for 2 h (37 °C) before initiating phosphorylation reactions by addition of substrate. CI, confident intervals. Data represent average values ± s.e.m., n = 3. c , Gel-ABPP data showing concentration-dependent blockade of YZ-01-A engagement of N112C-CCNE1 following incubation with I-125A or I-198 for 30 min or 90 min. Experiment was performed as described in . Data are from a single experiment. d , Gel-ABPP data showing that residual YZ-01-A reactivity with N112C-CCNE1 in presence of 1 μM of I-125A or I-198 is stereoselective (greater than signals generated with YZ-01-B) and site-specific (greater than signals generated with WT-CCNE1). Experiments were performed as described in . Data represent average values ± s.e.m., n = 2. e , NanoBRET data showing concentration-dependent blockade of active site-directed tracer K-10 (0.2 μM) binding to N112C-CCNE1:CDK2-NLuc (left) or WT-CCNE1:CDK2-NLuc complexes by dinaciclib, but not I-125A. NanoBRET assays were performed in lysates of HEK293T cells recombinantly expressing the CCNE1:CDK2-NLuc complexes. Data represent average values ± s.e.m., n = 3.

Journal: bioRxiv

Article Title: Expanding the ligandable proteome by paralog hopping with covalent probes

doi: 10.1101/2024.01.18.576274

Figure Lengend Snippet: a, b , ADP-Glo data showing effects of the indicated compounds on the activity of a purified WT-CCNE1:CDK2 ( a ) or WT-CCNE2:CDK2 ( b ) complexes as measured by phosphorylation of the C-terminal peptide of RB1 (left) or the histone H1 protein (right). The WT-CCNE:CDK2 complexes were pre-treated with compounds for 2 h (37 °C) before initiating phosphorylation reactions by addition of substrate. CI, confident intervals. Data represent average values ± s.e.m., n = 3. c , Gel-ABPP data showing concentration-dependent blockade of YZ-01-A engagement of N112C-CCNE1 following incubation with I-125A or I-198 for 30 min or 90 min. Experiment was performed as described in . Data are from a single experiment. d , Gel-ABPP data showing that residual YZ-01-A reactivity with N112C-CCNE1 in presence of 1 μM of I-125A or I-198 is stereoselective (greater than signals generated with YZ-01-B) and site-specific (greater than signals generated with WT-CCNE1). Experiments were performed as described in . Data represent average values ± s.e.m., n = 2. e , NanoBRET data showing concentration-dependent blockade of active site-directed tracer K-10 (0.2 μM) binding to N112C-CCNE1:CDK2-NLuc (left) or WT-CCNE1:CDK2-NLuc complexes by dinaciclib, but not I-125A. NanoBRET assays were performed in lysates of HEK293T cells recombinantly expressing the CCNE1:CDK2-NLuc complexes. Data represent average values ± s.e.m., n = 3.

Article Snippet: Briefly, different CCNE: CDK2 purified complexes at 4 ng μL −1 were mixed 1:1 with 2x compound stock (Both are made in kinase reaction buffer (40 mM Tris [pH = 7.6], 20 mM MgCl 2 , 0.1 mg mL −1 BSA and 50 μM DTT) and incubated at 37 °C for 1 h. Then 6 ng compound treated CCNE: CDK2 complexes (3 μL) were mixed with 2μL ATP/ CDK2 substrate mix to make final concentration of 150 μM ATP and 0.5 μg substrate per reaction (Substrate used is either histone H1(Sigma-Aldrich, 14-155) or RB1 C-terminal peptide (MyBioSource, MBS143254)), then incubated at room temperature for 1 h. Subsequently, 5 μL ADP-Glo reagent was added and incubated for 40 min at room temperature, followed with 10 μL kinase glo reagent and another 30-min incubation.

Techniques: Activity Assay, Purification, Concentration Assay, Incubation, Generated, Binding Assay, Expressing

Modulation of signaling pathways by ginsenosides in exerting cardioprotective effect. Abbreviation ; Parkin signaling pathway (PINK), interleuking-1-beta (IL-1β), interleukin-6 (IL6), tumor necrosis factor (TNF), extracellular signal-regulated kinase (ERK1/2), c-Jun N-terminal kinase (JNK), nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1), sirutnin1 (SIRT1), nuclear factor kappa B (NF-κB), phosphoinositide3-kinase (PI3K), protein kinase B (Akt), mitogen-activated protein kinases (MAPK), yes-associated protein (YAP), ginsenoside Rg1 (Rg1), ginsenoside Rg3 (Rg3), ginsenoside Rb1 (Rb1), ginsenoside F 2 (F 2 ).

Journal: Journal of Ginseng Research

Article Title: The role of ginseng and ginsenosides in ROS and cardiovascular disease

doi: 10.1016/j.jgr.2025.08.008

Figure Lengend Snippet: Modulation of signaling pathways by ginsenosides in exerting cardioprotective effect. Abbreviation ; Parkin signaling pathway (PINK), interleuking-1-beta (IL-1β), interleukin-6 (IL6), tumor necrosis factor (TNF), extracellular signal-regulated kinase (ERK1/2), c-Jun N-terminal kinase (JNK), nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1), sirutnin1 (SIRT1), nuclear factor kappa B (NF-κB), phosphoinositide3-kinase (PI3K), protein kinase B (Akt), mitogen-activated protein kinases (MAPK), yes-associated protein (YAP), ginsenoside Rg1 (Rg1), ginsenoside Rg3 (Rg3), ginsenoside Rb1 (Rb1), ginsenoside F 2 (F 2 ).

Article Snippet: Also, ginsenoside Rb1 restored cardiac function in isoproterenol (ISO) induced heart failure model in Sprague-Dawley (SD) rats by inhibiting the Fas-associated death domain [ ].

Techniques: Protein-Protein interactions